Cost-Effectiveness of Statin Therapy by Age Risk Model Calculator
Model inputs
Adjust the assumptions to explore a simplified primary-prevention statin cost-effectiveness scenario.
How to interpret this model
This is a transparent, simplified scenario calculator for exploring how baseline cardiovascular risk, assumed treatment effect, costs, quality-adjusted life-years (QALYs), and a willingness-to-pay (WTP) threshold affect estimated cost-effectiveness.
Calculation framework
- Horizon-adjusted risk = 1 − (1 − 10-year risk)horizon/10, assuming a constant hazard.
- Absolute risk reduction (ARR) = horizon-adjusted risk × assumed relative risk reduction (RRR).
- Net QALYs = QALYs gained from avoided events − pill disutility − diabetes-related QALY loss.
- Net costs = drug costs + monitoring costs − estimated costs avoided.
- Net monetary benefit (NMB) = (WTP × net QALYs) − net costs; NMB ≥ 0 is classified as cost-effective in this scenario.
Important model limitations
- This is not a validated clinical prediction tool or a full health-economic model. It does not model competing risks, adherence, discounting, recurrent events, survival, or uncertainty distributions.
- Age and sex are recorded but do not affect the equations; risk must be estimated externally using an appropriate validated tool.
- The horizon extrapolation, event-related QALY loss, diabetes-related disutility, and cost offsets are simplifying assumptions. They require local validation before research, policy, or clinical use.
- Results can be misleading if the input RRR, risk estimate, costs, or utility assumptions do not match the population, endpoint, and time horizon.
Evidence and references
Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015;314(2):142–150.
https://doi.org/10.1001/jama.2015.6822
Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
https://doi.org/10.1016/S0140-6736(12)60367-5
US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. 2022.
These sources provide context for statin benefit and economic modelling. They do not validate every equation or default value in this simplified calculator.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.